TIDMOXB

RNS Number : 8987Q

Oxford Biomedica PLC

01 November 2021

Long Term Incentive Plan Option Grant

London, UK - 01 November 2021: Oxford Biomedica plc ("Oxford Biomedica" or the "Company") (LSE:OXB), a leading gene and cell therapy Group announces that on 01 November 2021 nil-cost share options over shares of 50 pence each in the Company were granted to David Backer, who has joined the Senior Executive Team as Chief Commercial Officer, under the Oxford Biomedica 2015 Long Term Incentive Plan ("LTIP").

 
 Name of individual          Title            Number of      Total shares   Percentage of issued 
                                            shares subject    over which     share capital under 
                                              LTIP grant      options are          option 
                                                                 held 
                       Chief Commercial 
 David Backer               Officer            16,934           16,934             0.02% 
                      ------------------  ----------------  -------------  ---------------------

The LTIP awards are subject to a three year performance period and become exercisable from the third anniversary of the grant date, subject to the satisfaction of a performance condition.

As set out in the 2020 Directors' Remuneration Report, the performance condition is based on TSR (40% of the award, assessed over the three years from grant); revenue growth (40% of the award, assessed over financial years 2021, 2022 and 2023) and strategic milestones (20% of the award). Details of the measures are included in the 2020 Directors' Remuneration Report, other than as regards the strategic milestones, which are commercially sensitive and will be disclosed in due course.

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

Notification of Dealing Form

 
 1.   Details of the Person Discharging Managerial Responsibility 
       ("PDMR")/person closely associated with them ("PCA") 
 a)   Name                       David Backer 
     -------------------------  ----------------------------------------- 
 2.   Reason for the notification 
     -------------------------------------------------------------------- 
 a)   Position/status            Chief Commercial Officer 
     -------------------------  ----------------------------------------- 
 b)   Initial notification/      Initial Notification 
       amendment 
     -------------------------  ----------------------------------------- 
 3.   Details of the Issuer 
     -------------------------------------------------------------------- 
 a)   Name                       Oxford Biomedica plc 
     -------------------------  ----------------------------------------- 
 b)   LEI code                   213800S1GVQNXQ15K851 
     -------------------------  ----------------------------------------- 
 4.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place 
       where transactions have been conducted 
     -------------------------------------------------------------------- 
 a)   Description of             Ordinary Shares of 50 pence each 
       the financial              ISIN: GB00BDFBVT43 
       instrument 
       Identification 
       code 
     -------------------------  ----------------------------------------- 
 b)   Nature of the              Grant of awards over Ordinary Shares 
       transaction                under the Company's Long Term Incentive 
                                  Plan Plan. No consideration was paid 
                                  for the grant of awards. 
     -------------------------  ----------------------------------------- 
 c)   Price(s) and volumes(s)    LTIP Award 
                                   Price             Volume 
                                   Nil cost award    16,934 
                                                    ------- 
     -------------------------  ----------------------------------------- 
 d)   Aggregated information      Awards granted over 16,934 shares in 
       - Aggregate volume          total 
       - Price                     N/A 
     -------------------------  ----------------------------------------- 
 e)   Date of the transaction    11-01-2021 
     -------------------------  ----------------------------------------- 
 f)   Place of the transaction   Outside of trading venue 
     -------------------------  -----------------------------------------

-Ends-

 
 For further information, please contact: 
  Oxford Biomedica plc:                      Tel: +44 (0)1865 783 000 
   Natalie Walter, Company Secretary

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R)), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics and Boehringer Ingelheim, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally, the Group has signed a three-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 740 people. Further information is available at www.oxb.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHGZMGMGMNGMZM

(END) Dow Jones Newswires

November 01, 2021 06:08 ET (10:08 GMT)

Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Oxford Biomedica Charts.
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Oxford Biomedica Charts.